Summary
Eli Lilly and Company (LLY) filed an 8-K on May 4, 2022, detailing material modifications to its corporate governance documents following its Annual Shareholder Meeting held on May 2, 2022. The most significant update is the amendment to the Articles of Incorporation and Bylaws, which now allows shareholders to amend the Bylaws with a majority vote, in addition to the Board of Directors. This change shifts some bylaw amendment power from the Board directly to the shareholders. While shareholders approved this change, other significant governance proposals, such as eliminating the classified board structure and removing supermajority voting provisions, did not receive the required 80% shareholder approval. Additionally, several shareholder proposals related to lobbying activities and risk oversight were not approved. The appointment of Ernst & Young LLP as the independent auditor was ratified, and the compensation of named executive officers was approved on an advisory basis. The company also reported strong voting turnout, with approximately 90% of outstanding shares participating in the meeting.
Key Highlights
- 1Shareholders can now amend Eli Lilly's Bylaws with a majority vote, a change approved at the 2022 Annual Meeting.
- 2The exclusive right of the Board of Directors to amend Bylaws has been modified to include shareholder approval.
- 3Proposals to eliminate the classified board structure and remove supermajority voting provisions failed to meet the required 80% shareholder approval threshold.
- 4The appointment of Ernst & Young LLP as the independent auditor for 2022 was ratified by shareholders.
- 5Executive compensation was approved on an advisory basis.
- 6Several shareholder proposals concerning lobbying activities and risk oversight were not approved.
- 7A high voter turnout of approximately 90% of outstanding shares was recorded at the Annual Meeting.